Sichenzia Ross Ference LLP Represents Genetic Technologies Limited in $1.8 Million Registered Direct Offering

Press Release – New York, NY – April 3, 2020 – Sichenzia Ross Ference LLP today announced that it represented Genetic Technologies Limited (NASDAQ: GENE), a leader in the development of genetic risk assessment tests, in a registered direct offering of 1,028,574 American Depositary Shares (ADSs), each representing six hundred of the Company’s ordinary shares, at a purchase price of $1.75 per ADS.
The ADSs had been registered on a registration statement on Form F-3 (File No. 333-237152) declared effective by the Securities and Exchange Commission on March 23, 2020.
The Sichenzia Ross Ference LLP team was led by partners Darrin Ocasio and Avital Perlman, counsel Jeffrey Cahlon, and associate Yian Pan.
- Sichenzia Ross Ference Carmel LLP Represents R.F. Lafferty & Co., Inc. and Revere Securities LLC in $8.4 Million Initial Public Offering of Ordinary Shares of Plutus Financial Group Limited - February 6, 2025
- Sichenzia Ross Ference Carmel LLP Represents BriaCell Therapeutics in $3 Million Public Offering - February 6, 2025
- 美国思成律师事务所代表承销商Benjamin Securities和D. Boral Capital完成华谌科技纳斯达克上市 - February 6, 2025